Skip to the beginning of the images gallery

Nivolumab Biosimilar - Research Grade

Q: Is the Nivolumab biosimilar available in gram quantities?

Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Nivolumab biosimilar suitable for in vivo studies?

Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Nivolumab biosimilar target?

It is an unconjugated, non-therapeutic biosimilar analog of Nivolumab that binds human PD-1; for research use only (RUO).

In stock

Only %1 left

SKU

ICH4009

Add to Compare

Be the first to review this product

$315.00 - $19,890.00

Nivolumab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Product Specific Citations

Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry, 2023, 95, 44: 16116-16122.

Species Reactivity

Human

Target

PD-1

Concentration

>1mg/ml

Isotype

IgG4 kappa

Host

Humanized

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3001-100ml ICH3002-100ml ICH3003-100ml

Uniprot

Q15116

Gene Id

5133

Rrid

RRID:AB_2921529

Shipping Conditions

Blue ice

Background

This product is an unconjugated, non-therapeutic recombinant analog of nivolumab, a fully human IgG4 kappa antibody directed against programmed cell death protein 1 (PD-1, PDCD1; UniProt Q15116). It is supplied for research use only and is not the clinical drug, nor intended for human or veterinary use. Built around the PD-1 target, it is useful as a defined, reproducible reagent for studies of the PD-1/PD-L1 checkpoint axis: as a positive control or benchmarking tool in binding and blocking assays, for characterizing PD-1 expression on T cells, and as a comparator in biosimilarity, ADCC/ADC-development, and assay-qualification work. The IgG4 backbone limits effector function, consistent with a checkpoint-blocking mechanism rather than target-cell depletion. It is manufactured at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), available in bulk milligram-to-gram quantities, and formatted as an in-vivo-standard-grade reagent to support consistent preclinical and in-vitro experimentation. PD-1 (programmed cell death protein 1, encoded by PDCD1; UniProt Q15116) is a type I transmembrane immunoinhibitory receptor of the CD28/B7 family, expressed on activated T cells, B cells, NK cells, and myeloid subsets. Its cytoplasmic tail carries an ITIM and an ITSM that recruit the phosphatase SHP-2 upon ligand engagement. Binding of its ligands PD-L1 (CD274) and PD-L2 (CD273) dampens TCR and CD28 signaling, attenuating T-cell proliferation, cytokine production, and survival. This pathway maintains peripheral tolerance and limits immunopathology, but is co-opted in the tumor microenvironment and chronic infection to drive T-cell exhaustion. Blocking PD-1/PD-L1 engagement restores effector T-cell activity, the rationale underlying checkpoint-inhibitor immunotherapy.

Other Names

Programmed cell death protein 1, Pdcd1, CD279

Specificity

Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Nivolumab.

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Formulation

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Storage

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Use

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Bio X Cell Code

SIM0003

Suggested H1

Nivolumab (anti-PD-1) Biosimilar

Faq (q&a)

Q: Is the Nivolumab biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Nivolumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Nivolumab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Nivolumab that binds human PD-1; for research use only (RUO).

More Information

Product Benefits:

ichorbio's Nivolumab Biosimilar - Research Grade is manufactured in a cGMP compliant facility. Click here to view ichorbio’s complete list of anti-PD-1 antibodies and biosimilars.

Size:

ichorbio's research grade nivolumab biosimilar is available in the following sizes: 5mg, 10mg, 20mg, 50mg, 100mg ichorbio regularly manufactures bulk multi-gram amounts of our nivolumab biosimilar - please contact us for pricing.

Isotype Control:

Bulk Human IgG4 Isotype Control (IB4) [ICH2257]

Write Your Own Review

You're reviewing:Nivolumab Biosimilar - Research Grade

Your Rating

Rating